Intellia Therapeutics, Inc. (NTLA)

Revenue by Segment

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
Development of Gene Editing-Based Therapies	67.67M	57.88M	36.28M	52.12M	33.05M
Development of Gene Editing-Based Therapies Growth	16.92%	59.55%	-30.40%	57.69%	-43.01%
Total	67.67M	57.88M	36.28M	52.12M	33.05M
Total Growth	16.92%	59.55%	-30.40%	57.69%	-43.01%

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
United States	67.67M	57.88M	36.28M	52.12M	33.05M
United States Growth	16.92%	59.55%	-30.40%	57.69%	-43.01%
Total	67.67M	57.88M	36.28M	52.12M	33.05M
Total Growth	16.92%	59.55%	-30.40%	57.69%	-43.01%

Data Source: S&P Global Market Intelligence Last updated: May 11, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jun 15, 2026

Data Sources Report a data error